You are here

Dragon 'Wolverine' tablets

Safety advisory

13 March 2020

The Therapeutic Goods Administration (TGA) has tested a product labelled Dragon 'Wolverine' tablets and found that the tablets contain the undeclared substances sildenafil and chloramphenicol.

Dragon 'Wolverine' tablets pose a serious risk to your health and should not be taken.

Sildenafil is a prescription-only (S4) medicine in Australia. Chloramphenicol is a pharmacist-only (S3) antibiotic medicine for ophthalmic use only and a prescription-only medicine (S4) for any other use.

The supply of Dragon 'Wolverine' tablets containing the undisclosed sildenafil and chloramphenicol is illegal.

Dragon 'Wolverine' tablets have not been assessed by the TGA for quality, safety or efficacy as required under Australian legislation, and the place of manufacture is not approved by the TGA.

Information for consumers

If you or someone you know is taking Dragon 'Wolverine' tablets, stop immediately and take any remaining capsules to your local pharmacy for safe disposal.

If you have any concerns arising from your use of this product, consult your health care practitioner.

Action the TGA is taking

The TGA is working with the Australian Border Force (ABF) to help stop future shipments of Dragon 'Wolverine' tablets from entering Australia.

If these capsules are found at the border by the ABF they will be seized and destroyed.

We are advising consumers to exercise extreme caution when purchasing medicines from unknown overseas Internet sites, and we have produced a short video on the risks associated with buying medicines and medical devices online. Products purchased over the Internet:

  • may contain undisclosed and potentially harmful ingredients
  • may not meet the same standards of quality, safety and efficacy as those approved by the TGA for supply in Australia.

Report counterfeit medicines and medical devices

If you are worried about counterfeit medicines or medical devices, and want to report an issue, you can report the matter to the TGA:

Phone: 1800 020 653

Online: Report a perceived breach of the Therapeutic Goods Act or questionable practices relating to therapeutic products

Email: